Gestational diabetes mellitus (GDM) poses significant risks to both mother and fetus. Effective management strategies are essential to optimize outcomes. This article provides an in-depth guide to the most effective strategies for managing GDM.
Early detection and diagnosis of GDM is crucial. Universal screening, using either a one-step or two-step approach, is recommended. The one-step approach involves a 75g oral glucose tolerance test (OGTT) at 24-28 weeks gestation. The two-step approach involves a 50g glucose challenge test followed by a 100g OGTT for those who screen positive.
Medical nutrition therapy (MNT) is the cornerstone of GDM management. It involves individualized meal planning to ensure adequate maternal and fetal nutrition while controlling blood glucose levels. MNT should be initiated immediately after diagnosis and adjusted as needed throughout pregnancy.
Physical activity is another key component of GDM management. Moderate-intensity aerobic activity, such as brisk walking, for at least 150 minutes per week, is recommended. Exercise can improve insulin sensitivity and help control blood glucose levels.
If MNT and physical activity are insufficient to achieve glycemic control, pharmacologic therapy should be initiated. Insulin is the first-line treatment. However, oral hypoglycemic agents, such as metformin and glyburide, may be appropriate for some women.
Postpartum follow-up is essential to manage long-term risks associated with GDM. Women should be screened for type 2 diabetes at 6-12 weeks postpartum, and every 1-3 years thereafter. Lifestyle interventions to maintain a healthy weight and prevent diabetes should be implemented.
Effective management of GDM requires a comprehensive approach, including early detection, MNT, physical activity, pharmacologic therapy, and postpartum follow-up. By implementing these strategies, healthcare professionals can optimize outcomes for women with GDM and their infants.
1.
Research discovery halts childhood brain tumor before it forms
2.
Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.
3.
'CDC Must Be Investigated'; David Lynch, Bob Uecker Die; Nasal Epinephrine Warning
4.
Increasing Access to Prostate Cancer Drugs; Reducing Toxic Emissions; FTC Files a 'Charity' Suit.
5.
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
1.
Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025
2.
AI-Based Cancer Follow-Up Monitoring: Transforming Survivorship Care through Intelligent Surveillance
3.
Preventing Sarcopenia During Cancer Treatment
4.
Guidance for Managing Complex Anticoagulation
5.
Unlocking the Potential of Sarclisa: A New Hope for Cancer Treatment
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on Standard V/S High Risk Myeloma Treatment
2.
Navigating the Complexities of Ph Negative ALL - Part XIV
3.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation